Geneva, 18 August 2025 – Japan’s Ministry of Health, Labour and Welfare has invested an additional USD 1 million to support GARDP’s activities from April 2025 … Japan commits new funding to develop treatments for drug-resistant infections
Geneva and Tokyo, 18 July 2025 – GARDP and Institute of Science Tokyo have signed an agreement to optimize advanced compounds in GARDP’s antibiotic discovery … GARDP and Institute of Science Tokyo team up to unlock protein-compound structures that could lead to new antibiotics to treat drug-resistant bacterial infections
Accra (Ghana), 17 June 2025 – A new global collaboration has been launched to accelerate access to and effective use of diagnostics in the global effort … New global collaboration launched to tackle antimicrobial resistance through improved diagnostics
In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first … Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhoea in Adults
Geneva, 5 May 2025 – At the 25th meeting of the World Health Organization (WHO) Expert Committee on the Selection and Use of Essential Medicines, … GARDP calls for redefinition of antibiotics classification to reflect treatment realities and strengthen stewardship
Only 6.9% of people with drug-resistant infections in 8 large low- and middle-income countries received an appropriate antibiotic for their drug-resistant infection. Until now, the … GARDP research reveals that people with multidrug-resistant infections in low- and middle-income countries don’t have access to appropriate treatment
português │español Geneva, 24 March 2025 – The Global Antibiotic Research & Development Partnership (GARDP) is pleased to announce that Dr José Gomes Temporão has joined … Brazil’s former Health Minister Temporão appointed to GARDP Board
Français Geneva and Lausanne, Switzerland, 14 January 2025 – The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have … GARDP backs Debiopharm’s Swiss-developed compound to treat drug-resistant gonorrhoea infections
Seoul, 18 October 2024 – The Republic of Korea’s National Institute of Infectious Diseases (NIID) and the Global Antibiotic Research & Development Partnership (GARDP) have … The Republic of Korea’s National Institute of Infectious Diseases and GARDP team up to advance innovative clinical research on drug resistance
Geneva 30 September 2024 – The Global Antibiotic Research and Development Partnership (GARDP) has announced the appointment of a distinguished scientist and leader in the … Professor Glenda Gray appointed new GARDP Board Chair